science
FDA Medical Device Approval Pathway Examined in AI Newsletter
STAT's AI Prognosis newsletter published on May 13, 2026, reviewed the most common FDA medical device approval pathway and its characteristics. The edition also addressed sepsis algorithms and additional topics in health AI. Reporter Brittany Trang covers questions of whether AI tools work, who benefits and who might be harmed.
May 13, 1:25 PM·1m read1 source
StatAudio version
Tap play to generate a narrated version.
The coverage highlighted specific operational aspects that affect how artificial intelligence tools for medical use reach the market. The newsletter discussed sepsis algorithms as part of its review of health technology performance. It presented details on how such systems function within clinical settings and noted questions about their effectiveness.
Reporter Brittany Trang, who covers AI in health and medicine, wrote the edition. The reporter focuses on whether AI applications deliver intended results and which groups stand to gain or face risks from their deployment. The publication included information on upcoming events.
The writer plans to attend the STAT Breakthrough West Summit in San Francisco from May 18 to 20 and invited readers to arrange meetings on AI or data topics.
Prognosis newsletter addressed related subjects. Subsequent editions looked at whether AI scribes increase overall health care costs and featured comments from the Insilico Medicine CEO on AI applications in drug development.
